Retatrutide: FDA Status, Side Effects, and Trial Evidence

Retatrutide, also known by its development code LY3437943, is a single synthetic peptide developed by Eli Lilly. It activates three receptors in the incretin and glucagon family: the GLP-1 receptor, the GIP receptor and the glucagon receptor. That is why it is often called a triple agonist.

It is an investigational drug. Outside clinical trials, material sold online as research-grade product carries no assurance of quality, purity or safety and is not the same as the trial drug.

Structural studies have shown the molecule engaging all three receptors at once. The GLP-1 and GIP components are thought to reduce appetite and improve glycemic control, much like dual GIP and GLP-1 agonists such as tirzepatide.

The added glucagon component is proposed to raise energy expenditure and fat burning in the liver. That idea rests mainly on preclinical and mechanistic data. Direct human evidence on energy expenditure is limited.

Phase 2 randomized trials in adults with obesity and in adults with type 2 diabetes reported weight reduction and better glycemic control that grew with the amount of drug given. A small exploratory phase 2a substudy reported large drops in liver fat measured by MRI. That is a short-term imaging measure, not a biopsy or clinical outcome.

Two phase 3 randomized, double-blind, placebo-controlled trials were published in 2026, each lasting 80 weeks. In TRIUMPH-1, 2,339 adults with obesity and without diabetes had a mean weight change at 80 weeks of minus 23.7 and minus 25.0 percent in the two retatrutide groups of the primary comparison, against minus 3.9 percent with placebo. Subgroups with knee osteoarthritis or obstructive sleep apnea had larger reductions in knee pain and in breathing interruptions during sleep than with placebo.

In TRIUMPH-2, 1,152 adults with type 2 diabetes and a body-mass index of 27 or more lost more weight than with placebo, and glycemic control improved. Eli Lilly funded both trials. Their endpoints were weight, glycemic control and symptom scores, not long-term clinical events such as heart attacks or kidney failure.

The most common adverse events were gastrointestinal: nausea, vomiting, diarrhea and constipation, most prominent early in treatment while the amount was being stepped up. In the phase 2 obesity trial, heart rate rose with the amount of drug given, peaked at 24 weeks and then declined.

In TRIUMPH-2, low blood pressure and dysesthesia (unpleasant abnormal skin sensations) were reported more often than with placebo. Permanent discontinuation for adverse events or death was more frequent in two of the three retatrutide groups. Investigators judged all deaths in the trial unrelated to the study drug.

Safety beyond 80 weeks and at population scale is not established. Cardiovascular and kidney outcome trials are ongoing.

No regulator in the sources reviewed has approved retatrutide. FDA states that retatrutide cannot be used in compounding under federal law, and it has warned telehealth companies, ingredient distributors and sellers of products falsely labeled for research use. Health Canada's Drug Product Database lists no product containing it.

Retatrutide is not named on the WADA Prohibited List. WADA's S0 class covers any substance not addressed elsewhere on the List that has no regulatory approval for human therapeutic use, and it gives drugs in clinical development as an example. S0 substances are prohibited at all times, in and out of competition.